EMBC Breaking Class Action Lawsuit: Embecta Sued for Securities Fraud after Insulin Pen Issues Lead to 57% Stock Drop – Investors Notified to Contact BFA Law
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.
Key Details of the Embecta ($EMBC) Class Action:
